Induction of robust type-1 CD8(+) T-cell responses in WHO grade II low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC

PURPOSE: WHO grade II low-grade gliomas (LGGs) with high risk factors for recurrence are mostly lethal despite current treatments. We conducted a phase I study to evaluate the safety and immunogenicity of subcutaneous vaccinations with synthetic peptides for glioma-associated antigen (GAA) epitopes...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Cancer Res
Glavni autori: Okada, Hideho, Butterfield, Lisa H., Hamilton, Ronald L., Hoji, Aki, Sakaki, Masashi, Ahn, Brian J., Kohanbash, Gary, Drappatz, Jan, Engh, Johnathan, Amankulor, Nduka, Lively, Mark O., Chan, Michael D., Salazar, Andres M., Shaw, Edward G., Potter, Douglas M., Lieberman, Frank S.
Format: Artigo
Jezik:Inglês
Izdano: 2014
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4297523/
https://ncbi.nlm.nih.gov/pubmed/25424847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1790
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items